Two weeks ago, Novartis CEO Vas Narasimhan referred to the initial wave of drug pricing effects tied to the Inflation Reduction Act (IRA) as “manageable.” What the company appears to be finding ...
NovartisNVS stock slumped Thursday after the health giant reported light sales for its second-biggest moneymaker, Cosentyx. Cosentyx treats autoimmune conditions, including plaque psoriasis and ...
Novartis has started to feel the squeeze from generics to its top-selling drug, heart therapy Entresto. The erosion was obvious. After MSN Pharmaceuticals opened the floodgates to Entresto generics in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback